Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.56 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156532 | 0.87 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1CCR3L3MBTL4MBTD1 | |
| SCHEMBL16573965 | 0.82 | HPGD (0.66) | L3MBTL3L3MBTL1KDM4EALDH1A1HTT | |
| SCHEMBL24557368 | 0.82 | MGLL (0.64) | L3MBTL3L3MBTL1CA12CA1CA2 | |
| SCHEMBL12156597 | 0.82 | MGLL (0.64) | L3MBTL3L3MBTL1CA12CA1CA2 | |
| SCHEMBL3093793 | 0.81 | CA12 (0.65) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL1877596 | 0.81 | KDM4E (0.68) | L3MBTL3L3MBTL1CA12CA1CA2 | |
| SCHEMBL15271489 | 0.81 | CA12 (0.64) | L3MBTL3L3MBTL1CA12CA1CA2 | |
| SCHEMBL10293600 | 0.81 | KDM4E (0.79) | L3MBTL3L3MBTL1KDM4EALDH1A1POLB | |
| SCHEMBL14079950 | 0.81 | KDM4E (0.53) | L3MBTL3L3MBTL1CA12CA1CA2 | |
| SCHEMBL520565 | 0.80 | CA12 (0.63) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101981036-B | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2013-09-04 | — | — | CN | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | L3MBTL3 4289/4885L3MBTL1 3749/4885CA12 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.